Stay updated on GM T-cell Therapy in AML/BPDCN Clinical Trial
Sign up to get notified when there's something new on the GM T-cell Therapy in AML/BPDCN Clinical Trial page.
Latest updates to the GM T-cell Therapy in AML/BPDCN Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedDifference0.0%
- Check28 days agoChange DetectedRemoved the government funding status notice that previously appeared on the page; this change does not affect study data, eligibility, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%
- Check42 days agoChange DetectedMinor UI tweaks and an updated last-updated timestamp on the Study Details page; core content such as eligibility criteria and study design remains unchanged (To avoid being alerted by small changes, set an alert condition by clicking below).SummaryDifference0.4%
- Check71 days agoChange DetectedSite updated to v3.2.0 with an operational status notice from NIH; a previous term (CD4+/CD56+ hematodermic neoplasm) was removed. Overall, a standard version and status update with minor content pruning.SummaryDifference2%
- Check78 days agoChange DetectedThe page has been updated to version v3.1.0 and removes the term 'Acute lymphoblastic leukemia' from the content; no other significant changes are evident.SummaryDifference0.1%
- Check85 days agoChange DetectedThe page now includes newer date entries and regulatory notes (FDA-regulated drug status, study documents/links) while older update markers are removed; core regulatory information and timing metadata have been refreshed.SummaryDifference1%
Stay in the know with updates to GM T-cell Therapy in AML/BPDCN Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GM T-cell Therapy in AML/BPDCN Clinical Trial page.